|
1
|
Tian Z, Li L, Wang L, Hu Y and Li J:
Salivary gland neoplasms in oral and maxillofacial regions: A
23-year retrospective study of 6982 cases in an eastern Chinese
population. Int J Oral Maxillofac Surg. 39:235–242. 2010.
View Article : Google Scholar
|
|
2
|
Li J, Wang BY, Nelson M, Li L, Hu Y, Urken
ML and Brandwein-Gensler M: Salivary adenocarcinoma, not otherwise
specified: A collection of orphans. Arch Pathol Lab Med.
128:1385–1394. 2004.PubMed/NCBI
|
|
3
|
Spiro RH, Huvos AG and Strong EW: Adenoid
cystic carcinoma: Factors influencing survival. Am J Surg.
138:579–583. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang CY, Zhao YX, Xia RH, Han J, Wang BS,
Tian Z, Wang LZ, Hu YH and Li J: RASSF1A promoter hypermethylation
is a strong biomarker of poor survival in patients with salivary
adenoid cystic carcinoma in a Chinese population. PLoS One.
9:e1101592014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laurie SA and Licitra L: Systemic therapy
in the palliative management of advanced salivary gland cancers. J
Clin Oncol. 24:2673–2678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong M, How T, Kirkbride KC, Gordon KJ,
Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR and Blobe GC: The
type III TGF-beta receptor suppresses breast cancer progression. J
Clin Invest. 117:206–217. 2007. View
Article : Google Scholar
|
|
7
|
Bandyopadhyay A, López-Casillas F, Malik
SN, Montiel JL, Mendoza V, Yang J and Sun LZ: Antitumor activity of
a recombinant soluble betaglycan in human breast cancer xenograft.
Cancer Res. 62:4690–4695. 2002.PubMed/NCBI
|
|
8
|
Finger EC, Turley RS, Dong M, How T,
Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung
cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hempel N, How T, Cooper SJ, Green TR, Dong
M, Copland JA, Wood CG and Blobe GC: Expression of the type III
TGF-beta receptor is negatively regulated by TGF-beta.
Carcinogenesis. 29:905–912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Turley RS, Finger EC, Hempel N, How T,
Fields TA and Blobe GC: The type III transforming growth
factor-beta receptor as a novel tumor suppressor gene in prostate
cancer. Cancer Res. 67:1090–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharifi N, Hurt EM, Kawasaki BT and Farrar
WL: TGFBR3 loss and consequences in prostate cancer. Prostate.
67:301–311. 2007. View Article : Google Scholar
|
|
12
|
Gordon KJ, Kirkbride KC, How T and Blobe
GC: Bone morphogenetic proteins induce pancreatic cancer cell
invasiveness through a Smad1-dependent mechanism that involves
matrix metalloproteinase-2. Carcinogenesis. 30:238–248. 2009.
View Article : Google Scholar :
|
|
13
|
Mythreye K and Blobe GC: The type III
TGF-beta receptor regulates epithelial and cancer cell migration
through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad
Sci USA. 106:8221–8226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng W, Xia Q, Wu L, Chen S, He X, Zhang
L, Gao Q and Zhou H: Downregulation of TGF-beta receptor types II
and III in oral squamous cell carcinoma and oral
carcinoma-associated fibroblasts. BMC Cancer. 11:882011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gatza CE, Holtzhausen A, Kirkbride KC,
Morton A, Gatza ML, Datto MB and Blobe GC: Type III TGF-β receptor
enhances colon cancer cell migration and anchorage-independent
growth. Neoplasia. 13:758–770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jovanović B, Beeler JS, Pickup MW, Chytil
A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA and
Moses HL: Transforming growth factor beta receptor type III is a
tumor promoter in mesenchymal-stem like triple negative breast
cancer. Breast Cancer Res. 16:R692014. View
Article : Google Scholar
|
|
17
|
Chu WF, Wu DM, Liu W, Wu LJ, Li DZ, Xu DY
and Wang XF: Sulforaphane induces G2-M arrest and apoptosis in high
metastasis cell line of salivary gland adenoid cystic carcinoma.
Oral Oncol. 45:998–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vlantis K, Wullaert A, Sasaki Y,
Schmidt-Supprian M, Rajewsky K, Roskams T and Pasparakis M:
Constitutive IKK2 activation in intestinal epithelial cells induces
intestinal tumors in mice. J Clin Invest. 121:2781–2793. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J and Peng B: In vitro angiogenesis
and expression of nuclear factor kappaB and VEGF in high and low
metastasis cell lines of salivary gland adenoid cystic carcinoma.
BMC Cancer. 7:952007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu T, Tian L, Han Y, Vogelbaum M and Stark
GR: Dose-dependent cross-talk between the transforming growth
factor-beta and interleukin-1 signaling pathways. Proc Natl Acad
Sci USA. 104:4365–4370. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Monteleone G, Mann J, Monteleone I,
Vavassori P, Bremner R, Fantini M, Del Vecchio Blanco G, Tersigni
R, Alessandroni L, Mann D, et al: A failure of transforming growth
factor-beta1 negative regulation maintains sustained NF-kappaB
activation in gut inflammation. J Biol Chem. 279:3925–3932. 2004.
View Article : Google Scholar
|
|
22
|
You HJ, How T and Blobe GC: The type III
transforming growth factor-beta receptor negatively regulates
nuclear factor kappa B signaling through its interaction with
beta-arrestin2. Carcinogenesis. 30:1281–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng F, He K, Li X, Zhao D, Sun F, Zhang
Y, Nie D, Li X, Chu W, Sun Y, et al: Transient overexpression of
TGFBR3 induces apoptosis in human nasopharyngeal carcinoma CNE-2Z
cells. Biosci Rep. 33:e000292013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gatza CE, Oh SY and Blobe GC: Roles for
the type III TGF-beta receptor in human cancer. Cell Signal.
22:1163–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zanotto-Filho A, Delgado-Cañedo A,
Schröder R, Becker M, Klamt F and Moreira JC: The pharmacological
NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and
apoptosis in leukemia cells through ROS-mitochondria pathway
activation. Cancer Lett. 288:192–203. 2010. View Article : Google Scholar
|
|
26
|
Yan X, Shen H, Jiang H, Zhang C, Hu D,
Wang J and Wu X: External Qi of Yan Xin Qigong induces G2/M arrest
and apop tosis of androgen-independent prostate cancer cells by
inhibiting Akt and NF-kappa B pathways. Mol Cell Biochem.
310:227–234. 2008. View Article : Google Scholar
|
|
27
|
Zanotto-Filho A, Braganhol E, Battastini
AM and Moreira JC: Proteasome inhibitor MG132 induces selective
apoptosis in glioblastoma cells through inhibition of PI3K/Akt and
NFkappaB pathways, mitochondrial dysfunction, and activation of
p38-JNK1/2 signaling. Invest New Drugs. 30:2252–2262. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng M, Ekmekcioglu S, Walch ET, Tang CH
and Grimm EA: Inhibition of nuclear factor-kappaB and nitric oxide
by curcumin induces G2/M cell cycle arrest and apoptosis in human
melanoma cells. Melanoma Res. 14:165–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen W, Kirkbride KC, How T, Nelson CD, Mo
J, Frederick JP, Wang XF, Lefkowitz RJ and Blobe GC: Beta-arrestin
2 mediates endocytosis of type III TGF-beta receptor and
down-regulation of its signaling. Science. 301:1394–1397. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B
and Pei G: Identification of beta-arrestin2 as a G protein-coupled
receptor-stimulated regulator of NF-kappaB pathways. Mol Cell.
14:303–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Witherow DS, Garrison TR, Miller WE and
Lefkowitz RJ: Beta-arrestin inhibits NF-kappaB activity by means of
its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc
Natl Acad Sci USA. 101:8603–8607. 2004. View Article : Google Scholar : PubMed/NCBI
|
